Ü. S.	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER						
(REV 10-96)		4-20937/A/PCT						
TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION (2) (100 4500) 7 (4 R (5)						
DESIGNATED/ELECTED O	FFICE (DO/EO/US)							
CONCERNING A FILING UN	NDER 35 U.S.C. 371							
CONCERNING ATTENCE OF	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
INTERNATIONAL APPLICATION NO.	4 July 1997 (04.07.97)	5 July 1996 (05.07.96)						
PCT/EP97/03549 TITLE OF INVENTION	<u> </u>							
INHIBITORS OF THE INTERACTION BETV	VEEN P53 AND MDM2							
APPLICANT(S) FOR DO/EO/US								
LANE ET AL.								
Applicant herewith submits to the United States [	Designated/Elected Office (DO/EO/US) t	the following items and other information:						
1.								
ttems 11. to 16. below concern document(s)	or information included.							
11 TO An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.							
11. Li All Illionnation Diodossis Statement	a court shoot in compliance	e with 37 CFR 3.28 and 3.31 is included.						
12.  An assignment document for recording	g. A separate cover sheet in compliant							
<ul><li>13.  ☐ A FIRST preliminary amendment.</li><li>☐ A SECOND or SUBSEQUENT prelim</li></ul>	ninary amendment.							
14. A substitute specification.								
15. A change of power of attorney and/or	r address letter.							

16. 

Other items or information: unexecuted declaration

Sequence Listing and Diskette

U.S. APPLICATION NO. (if known, se	e 37 CFR 1.5)		PCT/EP97/03549 4-20937/A/				PCT			
			/EI 3 //03343	_				III ATIONS	PTO USE ONLY	
17.   The following fee						-	CALC	ULATION	PIOUSEUNLY	
BASIC NATIONAL FEE	(37 CFR 1.49	92(a) (1)-(5)):								
Search Report has been prepared by the EPO or JPO										
International preliminary examination fee paid to USPTO (37 CFR 1.482)										
						· ·				
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))										
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970										
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)										
ENTER APPROPRIATE BASIC FEE AMOUNT =						\$	840			
Surcharge of \$130 for furnishing the oath of declaration later than    20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						\$				
CLAIMS	NUMBE	R FILED	NUMBER EXTRA		RATE					
Total claims	25	- 20 =	5	Х	\$	18	\$	90		
Independent claims	9	-3=	6	X	\$	78	\$	468	<u>.</u>	
<b>MULTIPLE DEPENDEN</b>	T CLAIM(S)	if applicable)		+	\$	260	\$	1 200		
TOTAL OF ABOVE CALCULATIONS =							\$	1,398		
Reduction of 1/2 for filing	by small en	tity, if applica	ble. Verified Small Entity	Statem	ent must a	lso be	\$			
Med (Note 37 CFR 1.9,	1.21, 1.20).				SUBTO	TAL =	\$	1,398		
Processing fee of \$130 for furnishing the English translation later than 20 30 months from								-		
the earliest claimed prio	rity date (37	CFR 1.492(f))	·			<del>+</del> _	\$	1,398		
<u> </u>					TIONAL		\$	1,390		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property						\$				
TOTAL FEED ENGLOSED =						\$	1,398			
可 「 「 「 「 「 「 「 「 「 「 「 「 「							Amo	unt to be:	\$	
						_	refunded			
								charged	\$	
a. A check in the	amount of \$_		to cover the above for	es is er	closed.	,				
b. Please charge Deposit Account No. 19-0134 in the amount of \$1,398 to cover the above fees. A duplicate copy of this form is enclosed.										
c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence Customer No. 001095, Michael W. Gly Novartis Corpo Patent and Trac 564 Morris Ave Summit, NJ 07	which is curre nn ration demark Dept nue	ently:	My At Re	ra H/ M		Ph.D.	<del>Uh</del>		_	